![]() ![]() 4 Mass vaccination is key to achieving herd immunity and ending the pandemic. The cases submitted ranged from delayed large local reactions to pityriasis-rosea–like eruptions and reactivation of herpes simplex and varicella zoster. The American Academy of Dermatology and the International League of Dermatologic Societies COVID-19 Registry began collecting such cases in late December 2020. Of significance to dermatologists are the increasing reports of cutaneous reactions associated with these vaccines. Since then, several COVID-19 vaccines have been authorized and approved for distribution around the globe, with many more in the pipeline. ![]() 3 The United States followed suit days later, with the Food and Drug Administration (FDA) issuing Emergency Use Authorizations for both the Pfizer-BioNTech and Moderna vaccines. 2 By December 2, 2020, the United Kingdom became the first country to approve of and distribute the Pfizer-BioNTech BNT162b2 vaccine. On March 13, 2020, just 63 days after the genetic sequence of severe acute respiratory syndrome novel coronavirus 2 (SARS-CoV-2) was published, researchers began testing the first doses of a human COVID-19 vaccine. Scientists around the globe have raced to develop a long-term solution to impede viral transmission. ![]() One silver lining amid this crisis is that the tragedy has become a catalyst. 1 Although restrictions such as physical distancing are crucial to containment, these measures are only temporary solutions. As of April 22, 2021, the novel coronavirus disease 2019 (COVID-19) has sickened more than 142 million people and taken more than 3 million lives worldwide. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |